Stockscreener 앱 받기
3.55
0.28%
-0.01
시장 영업 전:
3.57
0.02
+0.56%
Abcellera Biologics Inc 주식(ABCL)의 최신 뉴스
Is AbCellera Biologics Inc a potential multi bagger2026 Sector Moves & Smart Money Movement Tracker - baoquankhu1.vn
Bear Alert: Is AbCellera Biologics Inc part of any ETF2026 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
AbCellera at KeyBanc Forum: Strategic Advances in Biotech By Investing.com - Investing.com Canada
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Hold" from Analysts - MarketBeat
AbCellera Biologics Q1 2025 Earnings Preview - MSN
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teladoc (TDOC), AbCellera Biologics (ABCL) and Cytokinetics (CYTK) - The Globe and Mail
A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress - simplywall.st
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Insider Monkey
13 Most Promising Penny Stocks Under $5 to Buy - Insider Monkey
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts - TipRanks
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Reports Full Year 2025 Business Results - BioSpace
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
What Sparked AbCellera Biologics To Soar Over 9% After Hours - Bitget
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges - GuruFocus
AbCellera Biologics Inc. (ABCL) reports Q4 loss, tops revenue estimates - MSN
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
AbCellera Biologics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-02-24 - Seeking Alpha
AbCellera Biologics Q4 Earnings Call Highlights - MarketBeat
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall - ChartMill
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera (ABCL) Achieves Remarkable Revenue Growth in FY25 - GuruFocus
AbCellera Biologics Inc. SEC 10-K Report - TradingView
Abcellera Biologics earnings missed by $0.35, revenue topped estimates - Investing.com South Africa
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know - Benzinga
AbCellera (NASDAQ: ABCL) 2025 results show revenue jump and strong liquidity - Stock Titan
AbCellera Biologics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Earnings Scheduled For February 24, 2026 - Benzinga
AbCellera Biologics (ABCL) Set to Announce FY Earnings - GuruFocus
AbCellera Biologics FY 2025 earnings preview - MSN
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges By GuruFocus - Investing.com Canada
AbCellera Biologics's Earnings Outlook - Benzinga
AbCellera Biologics Inc (ABCL) Misses Q4 2025 Earnings Estimates — EPS $-0.19 vs $-0.16 Expected - AlphaStreet
AbCellera Biologics Faces Stock Volatility Amid Strategic Decisions - timothysykes.com
AbCellera Biologics Inc (ABCL) down 23% since Q3 2025 results - MSN
Is AbCellera Biologics Inc affected by consumer sentimentJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
AbCellera Biologics Inc. (ABCL) Investor Outlook: Potential Upside of 205% Amidst Biotech Innovations - DirectorsTalk Interviews
AbCellera Biologics Inc. (NASDAQ:ABCL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Earnings on Tuesday - MarketBeat
0.02%
0.46%
자본화:
|
볼륨(24시간):